Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 07:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation
NCT00953706 · Vertex Pharmaceuticals Incorporated · PHASE2 · terminated · last registry update 2015-09-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Following review of results obtained from a pre-specified 6-month analysis of Part B data the study was terminated on the basis of futility.” | – | Registry record, Vertex Pharmaceuticals Incorporated |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CFTR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2016-06-13Phase 3 first posted: Vertex Pharmaceuticals Incorporated, LUM/IVA (NCT02797132)
- 2016-04-19Phase 3 first posted: Vertex Pharmaceuticals Incorporated, ivacaftor + Placebo (NCT02742519)
- 2016-04-01Phase 3 first posted: Vertex Pharmaceuticals Incorporated, IVA (NCT02725567)
- 2015-10-05Results posted on the registry: Vertex Pharmaceuticals Incorporated, Lumacaftor + Ivacaftor (NCT01225211)
- 2015-10-01Phase 3 first posted: Vertex Pharmaceuticals Incorporated, TEZ/IVA + IVA (NCT02565914)
- 2015-09-09Phase 3 first posted: Vertex Pharmaceuticals Incorporated, LUM/IVA + LUM/IVA (NCT02544451)
- 2015-09-01Results posted on the registry: Vertex Pharmaceuticals Incorporated, Placebo + Lumacaftor Plus Ivacaftor Combination (NCT01807949)
- 2015-08-31Results posted on the registry: Vertex Pharmaceuticals Incorporated, Lumacaftor Plus Ivacaftor Combination + Ivacaftor (NCT01807923)
- 2015-08-28Results posted on the registry: Vertex Pharmaceuticals Incorporated, VX-809 + Placebo (NCT00865904)
- 2015-08-05Phase 3 first posted: Vertex Pharmaceuticals Incorporated, VX-661 plus ivacaftor combination + Ivacaftor (NCT02516410)
- 2015-08-03Phase 3 first posted: Vertex Pharmaceuticals Incorporated, VX-809 + Placebo (NCT02514473)
- 2015-07-07Results posted on the registry: Vertex Pharmaceuticals Incorporated, Ivacaftor (NCT01117012)
- 2015-05-19Results posted on the registry: Vertex Pharmaceuticals Incorporated, Ivacaftor + Placebo-matched-to-ivacaftor tablet (NCT01685801)
- 2015-04-24Results posted on the registry: Vertex Pharmaceuticals Incorporated, Ivacaftor (NCT01705145)
- 2015-04-08Phase 3 first posted: Vertex Pharmaceuticals Incorporated, Ivacaftor + Tezacaftor/Ivacaftor (NCT02412111)
- 2015-03-18Phase 3 first posted: Vertex Pharmaceuticals Incorporated, VX-661/Ivacaftor + Ivacaftor (NCT02392234)
- 2015-03-17Phase 3 first posted: Vertex Pharmaceuticals Incorporated, Lumacaftor + Ivacaftor (NCT02390219)
- 2015-02-12Results posted on the registry: Vertex Pharmaceuticals Incorporated, Ivacaftor + Placebo (NCT01614457)
- 2015-01-27Phase 3 first posted: Vertex Pharmaceuticals Incorporated, VX-661 Plus Ivacaftor Combination + Ivacaftor (NCT02347657)
- 2014-10-29Results posted on the registry: Vertex Pharmaceuticals Incorporated, Ivacaftor + Placebo (NCT01614470)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision